Updated analysis shows highly significant improved overall survival (OS) for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NICIC-CTG and Scottish intergroup trial. - Stuart,G.; Bertelsen,K.; Mangioni,C. (Proc Am Soc Clin Oncol, 1998)